| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301) | RECRUITING | PHASE3 | 2025-05-06 | 2030-12-01 | 2027-12-01 |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | PHASE3 | 2024-10-16 | 2027-12 | 2026-06 |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2024-05-24 | 2027-07-15 | 2027-05-15 |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | RECRUITING | PHASE1, PHASE2 | 2024-01-18 | 2028-12 | 2027-06 |
| NCT06128551 | Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors | RECRUITING | PHASE1 | 2023-11-14 | 2026-11-30 | 2026-11-30 |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | RECRUITING | PHASE1 | 2023-09-07 | 2027-04-30 | 2026-04-30 |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-09-19 | 2025-12 | 2024-11 |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | RECRUITING | PHASE1 | 2022-05-31 | 2026-06-30 | 2026-05-29 |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | COMPLETED | PHASE2 | 2021-12-30 | 2024-08-29 | 2024-07-03 |
| NCT04774952 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | COMPLETED | PHASE1 | 2021-04-07 | 2024-06-28 | 2024-05-06 |
| NCT03989115 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC | COMPLETED | PHASE1, PHASE2 | 2019-07-02 | 2022-02-08 | 2022-02-08 |
| NCT03634982 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | UNKNOWN | PHASE1 | 2018-09-28 | 2023-05-31 | 2023-03-31 |